Αποτελέσματα Αναζήτησης
Key facts. Influenza activity started in week 47 of 2017 and returned to baseline levels in week 18 of 2018. Influenza viruses circulated at high levels between weeks 51 of 2017 and 13 of 2018. This is longer than in recent seasons and may have contributed to the severity of this season.
Influenza vaccination coverage rates (VCRs) among ‘older age groups’ (as defined in accordance with EU/EEA Member State recommendations - e.g. ≥55, ≥59, ≥60 or ≥65 years of age) for influenza seasons 2015–16, 2016– 17 and 2017-18 were reported by 19 EU/EEA Member States (Figure 4, Annex 4, Table 6).
3 Μαρ 2018 · Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A(H1N1)pdm09, −42 to 7% against influenza A(H3N2) and 36 to 54% against influenza B. 2017/18 influenza vaccine should be promoted where influenza still circulates.
It is recommended that trivalent vaccines for use in the 2017-2018 northern hemisphere influenza season contain the following: an A/Michigan/45/2015 (H1N1)pdm09-like virus; an A/Hong Kong/4801/2014 (H3N2)-like virus; and. a B/Brisbane/60/2008-like virus.
Optaflu is a trivalent surface antigen inactivated vaccine prepared in cell cultures manufactured by Novartis. In April 2007, Novartis received a positive opinion supporting European Union approval of Optaflu. It is the first influenza vaccine made in a mammalian cell line, rather than chicken eggs. [15]
Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A(H1N1)pdm09, -42 to 7% against influenza A(H3N2) and 36 to 54% against influenza B. 2017/18 influenza vaccine should be promoted where influenza still circulates.
Vaccine effectiveness against A(H1N1)pdm09 and the influenza B viruses is expected to be good, whereas effectiveness against A(H3N2) tends to be lower, similar to that seen in the 2016–2017 influenza season.
